lifestyle.marketresearchjournals.com

Author: UniXell Biotechnology Co., Ltd.

Unixell Biotech receives IND clearance by FDA for its Allogeneic iPSC-Derived cell therapy, UX-GIP001, for focal Epilepsy

March 13, 2026
Groundbreaking Study in the Journal of Clinical Investigation Advances Cell Therapy for Huntington’s Disease Treatment

October 20, 2025
Unixell Biotech reported a case study of UX-DA001, an iPSC-derived autologous cell therapy for Parkinson Diseases at MDS Congress 2025

October 16, 2025